Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 700 across all filing types
Latest filing 2017-08-02 Interim / Quarterly Rep…
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2017
2017-08-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content includes an announcement of financial results for the quarter ended June 30, 2017, referenced as a press release attached as Exhibit 99.1. The document itself does not contain detailed financial statements or substantive financial data but rather refers to the press release for the results. Additionally, it includes information about an amended employment agreement with the CEO, which is a management change announcement. However, the primary focus is the announcement of quarterly financial results via a press release. According to the classification rules, an 8-K announcing quarterly results with a press release is best classified as an Earnings Release (ER), since it is the initial announcement of quarterly financial results with key highlights only, not a full interim report. The document length (5374 characters) and content support this classification. Therefore, the filing type code is ER with high confidence.
2017-08-02 English
FORM 4
Director's Dealing
2017-07-27 English
FORM 4
Director's Dealing
2017-07-27 English
FORM 4
Director's Dealing
2017-07-27 English
FORM 4
Director's Dealing
2017-07-27 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.